Hong Kong investors are preparing for an influx of healthcare equities that could absorb $2 billion of capital in the coming weeks as two Chinese pharmaceutical companies roll out plans for initial public offerings.
Shanghai Pharmaceuticals, which is already listed in its home city, said last month that shareholders had approved the company’s H-share offering plan and that the China Securities Regulatory Commission had accepted its listing application. Last week, the company raised its original $1.2 billion target to between $1.5 billion and $1.8 billion, and said that it aims to list in Hong Kong by the end of this month.
On the same day, Shanghai Pharmaceuticals’...
¬ Haymarket Media Limited. All rights reserved.
